Overview

A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes

Status:
Recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

This is an open label phase II study of treatment with LEAF-4L6715 in patients who experience severe acute respiratory distress syndrome (ARDS) due to COVID-19, Sepsis or other Causes. The purpose of this study is to evaluate the improvement in PaO2/FiO2 by more than 25% in patients treated with LEAF-4L6715.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Institut de cancérologie Strasbourg Europe

Collaborators:

LEAF4Life LLC
LEAF4Life, Inc.